"Last year proved to be a record year for STRATA with preliminary full year revenue in the range of $35-$36 million, representing approximately 17-19% growth over the full year 2021," stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences. "This past year the team remained focused on growing the top-line through driving XTRAC usage, refurbishing and redeploying underutilized devices, and focusing on international sales. We are excited by these positive results and look forward to continuing this momentum throughout 2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SSKN:
- STRATA Skin Sciences Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference
- Strata Skin Sciences announces poster presentation on photopneumatic therapy
- STRATA Skin Sciences Expands into $300 Million Market with Exclusive Distribution Agreement in Mexico
- Strata Skin expands into $300M market with distribution agreement in Mexico
